Adenomyosis is a headache for many women. The main manifestation of adenomyosis is severe menstrual pain, which may start for no reason or may appear after a certain uterine operation, and gradually worsen to the point of being unbearable, and in some cases even requiring The pain may be unbearable and in some cases may require oral painkillers. It is usually combined with infertility, excessive menstruation, painful intercourse and an enlarged uterus. The cause of myasthenia gravis is unclear, and it is possible that it is related to damage to the endometrium, as well as to a genetic component. Pathologically, the appearance of the endometrium can be seen within the myometrium, and since these endometrial glands can bleed during menstruation as well as the endometrium in the uterine cavity, but the blood that comes out does not come out, it can cause severe pain. Myometriosis can often be detected by ultrasound if the uterine wall is thickened and appears structurally disturbed. MRI will also show similar findings. Often the blood Ca125 indicator will be elevated (no need to be nervous, it usually does not mean it is a sign of cancer). Dysmenorrhea and infertility due to myasthenia gravis are often difficult to manage and are currently a tricky condition to treat. In mild cases, oral pain medication can be used to control dysmenorrhea, and in patients with fertility requirements, active attempts to conceive can be made first. Myasthenia gravis often requires intervention if the symptoms of dysmenorrhea are more pronounced. A conservative treatment option is to try oral contraceptives first. Short-acting contraceptives can make some patients with dysmenorrhea less symptomatic, but the inconvenience is that they need to be taken orally for a long time. Mannorrhea is a new type of contraceptive ring that has emerged in recent years. It contains a progestin that is slowly released in the body and can last up to 5 years. The disadvantage of Mannorrhea is that it is not suitable for patients with fertility requirements, and if the uterus is large, it is also not suitable to be placed, and some patients may suffer from shedding after the IUD is placed. Some patients may experience a significant decrease in menstrual flow after IUD release. Some patients are also more likely to experience menstrual disorders during the first 6 months. If conservative treatment options are not effective, surgical treatment needs to be considered. Currently, surgical treatment is divided into conservative myeloablative lesion removal and radical hysterectomy. If you have fertility requirements, generally speaking, the hysterectomy is done, which can usually be done under minimally invasive laparoscopic surgery. If you have completed fertility and do not have fertility requirements, you can choose to have the lesion removed, but because myxomatous lesions are often diffuse, it is sometimes not easy to remove them cleanly or there is a recurrence in the removal of the uterus. If the dysmenorrhea is only caused by myometriosis, complete relief can usually be obtained, but in some patients with combined endometriosis, the dysmenorrhea may not be completely relieved. High-intensity focused ultrasound treatment (HEF) is a non-invasive treatment technique that has emerged in recent years (reply to “013” for more information). It is not an open surgery, but a technique that mediates ultrasound waves to the uterus through a concave and convex mirror-like focused ultrasound device to ablate lesions. No surgical scars and surgical adhesions to worry about. Studies suggest that the average degree of dysmenorrhea in patients after HEF treatment is reduced by 3 points, and many of our patients even have their dysmenorrhea symptoms disappear completely after treatment. Since there is no problem of surgical scars, even if the pain reoccurs, it can be treated twice. For patients with fertility requirements, there is no conclusion as to what the final pregnancy outcome will be due to the small amount of study data available.